{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:52:25Z","timestamp":1782337945578,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","award":["Innbio INB-009"],"award-info":[{"award-number":["Innbio INB-009"]}],"id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","award":["Innbio INB-009"],"award-info":[{"award-number":["Innbio INB-009"]}],"id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"publisher","award":["Innbio INB-009"],"award-info":[{"award-number":["Innbio INB-009"]}],"id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006393","name":"Universidad de Granada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006393","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Despite new treatments developed including immunomodulation using vaccines and cell therapies, mortality remains high due to the resistance mechanisms presented by these tumor cells and the function of the blood\u2013brain barrier that prevents the entry of most drugs. In this context of searching for new glioblastoma therapies, the study of the existing drugs to treat neurological disorder is gaining great relevance. The aim of this study was to determine, through a preliminary in vitro study on human glioblastoma (A172, LN229), anaplastic glioma (SF268) and neuroblastoma (SK-N-SH) cell lines, the possible antitumor activity of the active principles of several drugs (levomepromazine, haloperidol, lacosamide, valproic acid, levetiracetam, glatiramer acetate, fingolimod, biperiden and dextromethorphan) with the ability to cross the blood\u2013brain barrier and that are commonly used in neurological disorders. Results showed that levetiracetam, valproic acid, and haloperidol were able to induce a relevant synergistic antitumor effect when associated with the chemotherapy currently used in clinic (temozolomide). Regarding the mechanism of action, haloperidol, valproic acid and levomepromazine caused cell death by apoptosis, while biperiden and dextromethorphan induced autophagy. Fingolimod appeared to have anoikis-related cell death. Thus, the assayed drugs which are able to cross the blood\u2013brain barrier could represent a possibility to improve the treatment of neural tumors, though future in vivo studies and clinical trials will be necessary to validate it.\n<\/jats:p>","DOI":"10.1007\/s12640-022-00606-3","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:47:38Z","timestamp":1669790858000},"page":"1645-1652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines"],"prefix":"10.1007","volume":"40","author":[{"given":"Kevin","family":"Doello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mesas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Qui\u00f1onero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Rama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Perazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"606_CR1","unstructured":"Chou T, Martin N (2005) CompuSyn for drug combinations and for general dose-effect analysis. PC Software for quantization of synergism and antagonism and determination of IC50, ED50 and LD50. In: CompuSyn software. ComboSyn Inc., Paramus (NJ)"},{"key":"606_CR2","doi-asserted-by":"publisher","unstructured":"Grech N, Dalli T, Mizzi S et al (2020) Rising incidence of glioblastoma multiforme in a well-defined population Cureus 12. https:\/\/doi.org\/10.7759\/cureus.8195","DOI":"10.7759\/cureus.8195"},{"key":"606_CR3","doi-asserted-by":"publisher","unstructured":"Jacobs KA, Andr\u00e9\u2010Gr\u00e9goire G, Maghe C et al (2020) Paracaspase MALT1 regulates glioma cell survival by controlling endo\u2010lysosome homeostasis. EMBO J 39. https:\/\/doi.org\/10.15252\/embj.2019102030","DOI":"10.15252\/embj.2019102030"},{"key":"606_CR4","doi-asserted-by":"publisher","unstructured":"Kamarudin MNA, Parhar I (2019) Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: a comprehensive review. Oncotarget 10:3952\u20133977. https:\/\/doi.org\/10.18632\/oncotarget.26994","DOI":"10.18632\/oncotarget.26994"},{"key":"606_CR5","unstructured":"Kanderi T, Gupta V (2022) Glioblastoma Multiforme. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"606_CR6","doi-asserted-by":"publisher","unstructured":"Lee C-Y, Lai H-Y, Chiu A, et al (2016) The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol 127:445\u2013453. https:\/\/doi.org\/10.1007\/s11060-016-2056-6","DOI":"10.1007\/s11060-016-2056-6"},{"key":"606_CR7","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.3390\/ijms18112448","volume":"18","author":"S Mahajan-Thakur","year":"2017","unstructured":"Mahajan-Thakur S, Bien-M\u00f6ller S, Marx S et al (2017) Sphingosine 1-phosphate (S1P) signaling in glioblastoma multiforme\u2014a systematic review. Int J Mol Sci 18:2448. https:\/\/doi.org\/10.3390\/ijms18112448","journal-title":"Int J Mol Sci"},{"key":"606_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000401","volume":"4","author":"A Mathias","year":"2017","unstructured":"Mathias A, Perriot S, Canales M et al (2017) Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate. Neurol Neuroimmunol Neuroinflammation 4:e401. https:\/\/doi.org\/10.1212\/NXI.0000000000000401","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"606_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-020-03448-1","volume":"151","author":"R Medikonda","year":"2021","unstructured":"Medikonda R, Dunn G, Rahman M et al (2021) A review of glioblastoma immunotherapy. J Neurooncol 151:41\u201353. https:\/\/doi.org\/10.1007\/s11060-020-03448-1","journal-title":"J Neurooncol"},{"key":"606_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1593\/neo.07130","volume":"9","author":"V M\u00e9galizzi","year":"2007","unstructured":"M\u00e9galizzi V, Mathieu V, Mijatovic T et al (2007) 4-IBP, a \u03c31 Receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia N Y N 9:358\u2013369","journal-title":"Neoplasia N Y N"},{"key":"606_CR11","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1212\/WNL.0000000000013005","volume":"98","author":"J Pallud","year":"2022","unstructured":"Pallud J, Huberfeld G, Dezamis E et al (2022) Effect of levetiracetam use duration on overall survival of isocitrate dehydrogenase wild-type glioblastoma in adults: an observational study. Neurology 98:e125\u2013e140. https:\/\/doi.org\/10.1212\/WNL.0000000000013005","journal-title":"Neurology"},{"key":"606_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/BIOMEDICINES8120595","volume":"8","author":"F Papadopoulos","year":"2020","unstructured":"Papadopoulos F, Isihou R, Alexiou GA et al (2020) Haloperidol induced cell cycle arrest and apoptosis in glioblastoma cells. Biomedicines 8:1\u201312. https:\/\/doi.org\/10.3390\/BIOMEDICINES8120595","journal-title":"Biomedicines"},{"key":"606_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A et al (2020) Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma. JAMA Oncol 6:1\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1024","journal-title":"JAMA Oncol"},{"issue":"10","key":"606_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-67697-w","volume":"101","author":"TH Roh","year":"2020","unstructured":"Roh TH, Moon JH, Park HH et al (2020) Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. Sci Rep 101(10):1\u20137. https:\/\/doi.org\/10.1038\/s41598-020-67697-w","journal-title":"Sci Rep"},{"key":"606_CR15","doi-asserted-by":"publisher","unstructured":"Seo E-J, Efferth T (2016) Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy. Oncotarget 7:16818\u201316839. https:\/\/doi.org\/10.18632\/oncotarget.7605","DOI":"10.18632\/oncotarget.7605"},{"key":"606_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-021-00280-1","volume":"9","author":"A Tripathi","year":"2021","unstructured":"Tripathi A, Kashyap A, Tripathi G et al (2021) Tumor reversion: a dream or a reality. Biomark Res 9:31. https:\/\/doi.org\/10.1186\/s40364-021-00280-1","journal-title":"Biomark Res"},{"key":"606_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncol 22:1073\u20131113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106","journal-title":"Neuro-Oncol"},{"key":"606_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3171\/2019.12.JNS192682","volume":"134","author":"T Yamada","year":"2020","unstructured":"Yamada T, Tsuji S, Nakamura S et al (2020) Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. J Neurosurg 134:701\u2013710. https:\/\/doi.org\/10.3171\/2019.12.JNS192682","journal-title":"J Neurosurg"},{"key":"606_CR19","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.7150\/jca.32475","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang H, Wang R, Yu Y et al (2019) Glioblastoma treatment modalities besides surgery. J Cancer 10:4793\u20134806. https:\/\/doi.org\/10.7150\/jca.32475","journal-title":"J Cancer"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-022-00606-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-022-00606-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-022-00606-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T04:39:59Z","timestamp":1672288799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12640-022-00606-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s12640-022-00606-3","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors indicate that the views expressed in the submitted article are their own and not an official position of the institution or the funding agency.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimers"}}]}}